Bio
Bio
David provides strategic guidance to Elaia's biotech portfolio companies on technology development, financing strategy, regulatory pathways, and partnerships with pharmaceutical companies.
David is co-founder and Executive Vice President for CMC and Manufacturing at Cellectis, a clinical-stage bio-pharmaceutical company listed on NasdaQ and Euronext. He serves on the boards of Hephaistos Pharma, hema.to and Aqemia. Over 25 years, he took Cellectis from a technology concept-based startup to a clinical-stage company, raising over €800 million through private investors, IPOs, follow-ons and industrial partnerships, demonstrating expertise in building and financing deep biotech companies.
Prior to Cellectis, David worked in industrial program management at the French Department of Defense (DGA). He holds a degree from École Polytechnique and a PhD in molecular virology from Institut Pasteur, with postdoctoral work at Emory University.